GlaxoSmithKline Pakistan Limited (PSX:GLAXO)
Pakistan · Delayed Price · Currency is PKR 358.37
-6.27 (-1.72%)
At close: May 11, 2026
GlaxoSmithKline Pakistan Income Statement
Financials in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 67,349 | 65,901 | 61,188 | 49,661 | 41,842 | 36,661 | |
Revenue Growth (YoY) | 10.13% | 7.70% | 23.21% | 18.69% | 14.13% | 4.48% |
Cost of Revenue | 42,008 | 41,618 | 45,910 | 46,245 | 34,505 | 26,787 |
Gross Profit | 25,341 | 24,283 | 15,277 | 3,416 | 7,336 | 9,874 |
Selling, General & Admin | 7,560 | 7,283 | 6,380 | 6,528 | 5,139 | 3,857 |
Other Operating Expenses | 744.31 | 640.12 | -1,355 | -5,077 | -2,871 | -856 |
Operating Expenses | 8,304 | 7,924 | 5,026 | 1,451 | 2,268 | 3,001 |
Operating Income | 17,037 | 16,360 | 10,252 | 1,965 | 5,068 | 6,873 |
Interest Expense | - | -43.12 | -19.28 | -6.52 | -5.37 | -5.43 |
Interest & Investment Income | 565.77 | 518.14 | 538.91 | 277.02 | 829.54 | 374.94 |
Currency Exchange Gain (Loss) | -51.16 | -51.16 | -221.11 | 68.24 | -703.51 | -156.49 |
Other Non Operating Income (Expenses) | -73.27 | -73.27 | -72.38 | -56.48 | -7.37 | -2.52 |
EBT Excluding Unusual Items | 17,478 | 16,710 | 10,478 | 2,247 | 5,182 | 7,084 |
Merger & Restructuring Charges | -91.29 | -91.29 | -5.61 | -215.25 | -146.51 | -321.57 |
Gain (Loss) on Sale of Assets | 74.07 | 74.07 | 21.88 | 82.76 | 124.62 | 633.9 |
Asset Writedown | -9.84 | -9.84 | -18.39 | -6.01 | -54.02 | -15.54 |
Other Unusual Items | - | - | - | 68.56 | - | 43.88 |
Pretax Income | 17,451 | 16,683 | 10,476 | 2,177 | 5,106 | 7,424 |
Income Tax Expense | 6,942 | 6,658 | 3,940 | 1,643 | 2,643 | 2,070 |
Earnings From Continuing Operations | 10,509 | 10,025 | 6,536 | 533.95 | 2,463 | 5,354 |
Net Income | 10,509 | 10,025 | 6,536 | 533.95 | 2,463 | 5,354 |
Net Income to Common | 10,509 | 10,025 | 6,536 | 533.95 | 2,463 | 5,354 |
Net Income Growth | 29.79% | 53.39% | 1124.09% | -78.32% | -54.00% | 58.64% |
Shares Outstanding (Basic) | 318 | 318 | 318 | 318 | 318 | 318 |
Shares Outstanding (Diluted) | 318 | 318 | 318 | 318 | 318 | 318 |
EPS (Basic) | 33.00 | 31.48 | 20.52 | 1.68 | 7.73 | 16.81 |
EPS (Diluted) | 33.00 | 31.48 | 20.52 | 1.68 | 7.73 | 16.81 |
EPS Growth | 29.79% | 53.39% | 1124.09% | -78.32% | -54.00% | 58.64% |
Free Cash Flow | 7,756 | 6,081 | 2,282 | 234.56 | -4,694 | 3,683 |
Free Cash Flow Per Share | 24.35 | 19.09 | 7.17 | 0.74 | -14.74 | 11.57 |
Dividend Per Share | - | 17.000 | 10.000 | - | - | 7.000 |
Dividend Growth | - | 70.00% | - | - | - | 7.69% |
Gross Margin | 37.63% | 36.85% | 24.97% | 6.88% | 17.53% | 26.93% |
Operating Margin | 25.30% | 24.82% | 16.75% | 3.96% | 12.11% | 18.75% |
Profit Margin | 15.60% | 15.21% | 10.68% | 1.07% | 5.89% | 14.61% |
Free Cash Flow Margin | 11.52% | 9.23% | 3.73% | 0.47% | -11.22% | 10.05% |
EBITDA | 18,376 | 17,687 | 11,344 | 2,881 | 5,910 | 7,634 |
EBITDA Margin | 27.28% | 26.84% | 18.54% | 5.80% | 14.12% | 20.82% |
D&A For EBITDA | 1,339 | 1,327 | 1,093 | 916.48 | 841.69 | 760.47 |
EBIT | 17,037 | 16,360 | 10,252 | 1,965 | 5,068 | 6,873 |
EBIT Margin | 25.30% | 24.82% | 16.75% | 3.96% | 12.11% | 18.75% |
Effective Tax Rate | 39.78% | 39.91% | 37.61% | 75.48% | 51.76% | 27.88% |
Advertising Expenses | - | - | - | 22.89 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.